|
IDENTIFICATION OF ABERRANT PATHWAY AND NETWORK ACTIVITY FROM HIGH-THROUGHPUT DATA |
|
|
|
|
1 | (6) |
|
|
|
|
|
SSLPred: Predicting Synthetic Sickness Lethality |
|
|
7 | (12) |
|
|
|
|
Predicting the Effects of Copy-Number Variation in Double and Triple Mutant Combinations |
|
|
19 | (12) |
|
|
|
|
|
Integrative Network Analysis to Identify Aberrant Pathway Networks in Ovarian Cancer |
|
|
31 | (12) |
|
|
|
|
|
|
|
|
|
Role of Synthetic Genetic Interactions in Understanding Functional Interactions Among Pathways |
|
|
43 | (12) |
|
|
|
|
Discovery of Mutated Subnetworks Associated with Clinical Data in Cancer |
|
|
55 | (12) |
|
|
|
|
|
INTRINSICALLY DISORDERED PROTEINS: ANALYSIS, PREDICTION, SIMULATION, AND BIOLOGY |
|
|
|
|
67 | (3) |
|
|
|
|
Quasi-Anharmonic Analysis Reveals Intermediate States in the Nuclear Co-Activator Receptor Binding Domain Ensemble |
|
|
70 | (12) |
|
|
|
|
|
|
|
Efficient Construction of Disordered Protein Ensembles in a Bayesian Framework with Optimal Selection of Conformations |
|
|
82 | (12) |
|
|
|
|
Correlation Between Posttranslational Modification and Intrinsic Disorder in Protein |
|
|
94 | (10) |
|
|
|
Intrinsic Disorder Within and Flanking the DNA-Binding Domains of Human Transcription Factors |
|
|
104 | (12) |
|
|
|
|
Intrinsic Protein Disorder and Protein-Protein Interactions |
|
|
116 | (12) |
|
|
|
|
|
|
|
|
|
Subclassifying Disordered Proteins by the CH-CDF Plot Method |
|
|
128 | (12) |
|
|
|
|
|
|
|
|
|
Coevolved Residues and the Functional Association for Intrinsically Disordered Proteins |
|
|
140 | (12) |
|
|
|
Cryptic Disorder: An Order-Disorder Transformation Regulates the Function of Nucleophosmin |
|
|
152 | (12) |
|
|
|
Functional Annotation of Intrinsically Disordered Domains by Their Amino Acid Content Using IDD Navigator |
|
|
164 | (12) |
|
|
|
|
|
|
On the Complementarity of the Consensus-Based Disorder Prediction |
|
|
176 | (12) |
|
|
|
Modulating Protein--DNA Interactions by Post-Translational Modifications at Disordered Regions |
|
|
188 | (12) |
|
|
|
|
MICROBIOME STUDIES: ANALYTICAL TOOLS AND TECHNIQUES |
|
|
|
|
200 | (3) |
|
|
|
|
|
Estimating Population Diversity with Unreliable Low Frequency Counts |
|
|
203 | (10) |
|
|
|
|
|
Comparisons of Distance Methods for Combining Covariates and Abundances in Microbiome Studies |
|
|
213 | (12) |
|
|
|
|
|
|
Proteotyping of Microbial Communities by Optimization of Tandem Mass Spectrometry Data Interpretation |
|
|
225 | (10) |
|
|
|
|
|
|
|
phyloseq: A Bioconductor Package for Handling and Analysis of High-Throughput Phylogenetic Sequence Data |
|
|
235 | (12) |
|
|
|
SEPP: SATe -Enabled Phylogenetic Placement |
|
|
247 | (12) |
|
|
|
|
Artificial Functional Difference Between Microbial Communities Caused by Length Difference of Sequencing Reads |
|
|
259 | (12) |
|
|
|
|
MetaDomain: A Profile HMM-Based Protein Domain Classification Tool for Short Sequences |
|
|
271 | (12) |
|
|
|
MODELING HOST-PATHOGEN INTERACTIONS: COMPUTATIONAL BIOLOGY AND BIOINFORMATICS FOR INFECTIOUS DISEASE RESEARCH |
|
|
|
|
283 | (4) |
|
|
|
|
|
Structural Models for Host-Pathogen Protein-Protein Interactions: Assessing Coverage and Bias |
|
|
287 | (12) |
|
|
|
Identification of Cell Cycle-Regulated, Putative Hyphal Genes in Candida Albicans |
|
|
299 | (12) |
|
|
|
|
Determining Confidence of Predicted Interactions Between HIV-1 and Human Proteins Using Conformal Method |
|
|
311 | (12) |
|
|
|
|
|
PERSONALIZED MEDICINE: FROM GENOTYPES AND MOLECULAR PHENOTYPES TOWARDS COMPUTED THERAPY |
|
|
|
|
323 | (4) |
|
|
|
|
|
Finding Genome-Transcriptome-Phenome Associations with Structured Association Mapping and Visualization in GenAMap |
|
|
327 | (12) |
|
|
|
|
|
Interpretome: A Freely Available, Modular, and Secure Personal Genome Interpretation Engine |
|
|
339 | (12) |
|
|
|
|
|
|
|
|
|
|
A Kinase Inhibition Map Approach for Tumor Sensitivity Prediction and Combination Therapy Design for Targeted Drugs |
|
|
351 | (12) |
|
|
|
Mixture Model for Sub-Phenotyping in GWAS |
|
|
363 | (12) |
|
|
|
|
|
TEXT AND KNOWLEDGE MINING FOR PHARMACOGENOMICS: GENOTYPEPHENOTYPE-DRUG RELATIONSHIPS |
|
|
|
|
375 | (1) |
|
|
|
|
|
The Extraction of Pharmacogenetic and Pharmacogenomic Relations -- A Case Study Using PharmGKB |
|
|
376 | (12) |
|
|
|
|
Linking PharmGKB to Phenotype Studies and Animal Models of Disease for Drug Repurposing |
|
|
388 | (12) |
|
|
|
Dietrich Rebholz-Schuhmann |
|
|
|
|
Integrating VA's NDF-RT Drug Terminology with PharmGKB: Preliminary Results |
|
|
400 | (10) |
|
|
|
|
|
|
|
Discovery and Explanation of Drug-Drug Interactions via Text Mining |
|
|
410 | (12) |
|
|
|
|
Ranking Gene-Drug Relationships in Biomedical Literature Using Latent Dirichlet Allocation |
|
|
422 | (12) |
|
|
|
|
|
|
|
|
The Structure and Function of Chromatin and Chromosomes |
|
|
434 | (7) |
|
|
|
|
|
|
Law, Bioethics and the Current Status of Ownership, Privacy, Informed Consent in the Genomic Age |
|
|
441 | (1) |
|
|
|
Systems Pharmacogenomics--Bridging the Gap |
|
|
442 | |
|
|
|
|
|
|